PTC Therapeutics (PTCT) Appoints Alethia Young to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
June 9, 2022 8:00 AM EDTSOUTH PLAINFIELD, N.J., June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing. She is currently the Chief Financial Officer of Graphite Bio where she oversees the company's finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy.
... More



